SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor

Official title

A Phase Ib/III Study of SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor

Overview

This study consists of two research phases: Phase Ib (includes dose escalation stage and efficacy expansion stage): To explore the safety, tolerability and initial efficacy of SHR-A1904 in the treatment of CLDN18.2-positive advanced solid tumors, and to determine the recommended dose and recommended population for the Phase III combination study. Phase III: A randomized, Open-Label, multicenter clinical study of SHR-A1904 combined with chemotherapy and immunotherapy Versus chemotherapy combined with immunotherapy for CLDN18.2-positive advanced solid tumors.

Interventions

• Drug SHR-A1904; Adebrelimab
  SHR-A1904 combined with Adebrelimab: SHR-A1904+ Adebrelimab
• Drug SHR-A1904; CAPOX; Adebrelimab
  SHR-A1904 combined with Adebrelimab and CAPOX (Capecitabine, Oxaliplatin)

Primary outcome measures

• Incidence and severity of AE [Time frame: Up to follow-up period, approximately 24 months]
• Dose Limiting Toxicity (DLT) [Time frame: approximately 24 months]
• Maximal Tolerable Dose (MTD) [Time frame: approximately 24 months]
• Phase III Recommended Dose (RP3D) [Time frame: approximately 24 months]
• Progression-free survival (PFS) assessed by blind Independent Center Review (BICR) based on RECIST 1.1 criteria [Time frame: approximately 36 months]

Secondary outcome measures (6)

• SHR-A1904 toxin binding antibody [Time frame: approximately 24 months]
• SHR-A1904 Total antibody [Time frame: approximately 24 months]
• Immunogenicity indicators of SHR-A1904: drug resistant antibody (ADA) and neutralizing antibody (NAb) [Time frame: approximately 24 months]
• Expression level of CLDN18.2 in tumor tissues [Time frame: approximately 24 months]
• Overall survival (OS) [Time frame: approximately 36 months]
• Incidence and severity of AE [Time frame: approximately 36 months]

Eligibility criteria

Inclusion criteria

• Age 18 to 75 years old (including boundary values);
• Volunteer to participate in this clinical study and sign informed consent;
• ECOG score 0-1;
• Expected survival ≥3 months;
• Pathologically confirmed locally advanced unresectable or metastatic solid tumors;
• positive CLDN18.2 expression in tumor tissue;
• There is at least one measurable lesion that meets the RECIST 1.1 criteria;
• Adequate bone marrow and organ function.

Exclusion criteria

• Plan to receive any other antitumor therapy during this trial; Received other investigational drugs or treatments that are not on the market within 4 weeks prior to the first administration; Anti-tumor therapy, such as chemotherapy, radiotherapy, biotherapy, targeted therapy or immunotherapy, was received within 4 weeks before the first administration of the study drug. Palliative radiotherapy or local therapy within 2 weeks before the first administration of the study drug; Had major surgery other than diagnosis or biopsy within the 4 weeks prior to the first administration or randomization and required elective surgery during the trial.
• HER2 expression in tumor tissue is positive.
• The adverse reactions of previous anti-tumor therapy has not recovered to NCI-CTCAE v5.0 grade≤ 1.
• Has ≥ grade 2 peripheral sensory neuropathy.
• Has an allergic reaction to any of the components treated in this study, or are allergic to humanized monoclonal antibody products.
• Has a history or current history of meningeal metastasis; or active brain metastases.
• Presence of dysphagia or other factors affecting the use of oral medications.
• Additional malignancy within the five years prior to the first administration or randomization.
• Has an active autoimmune disease or a history of autoimmune disease.
• Received systemic use of corticosteroids or other immunosuppressants for immunosuppressive effects within 14 days prior to the first administration or randomization.
• Has a history of clinically significant lung disease.
• Has serosal effusion ≥ grade 3 (based on NCI CTCAE5.0 criteria).
• There was an active infection requiring systemic treatment within 2 weeks prior to the first administration or randomization.
• A history of immunodeficiency, including a positive HIV test; Presence of active hepatitis B or hepatitis C.
• People who have previously received allogeneic hematopoietic stem cell transplantation or organ transplantation.
• Has severe cardiovascular and cerebrovascular diseases.
• Gastrointestinal perforation and/or gastrointestinal fistula within the last 6 months prior to the first administration or randomization; Active gastrointestinal bleeding occurred 3 months before the first administration or randomization.
• In the investigator's judgment, the subject has other factors that could have affected the study results or led to the forced termination of the study.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Non-randomized

Model

Parallel assignment

Masking

Open label

Primary purpose

Treatment

Study locations

China · 1 center

• Sun Yat-sen University Cancer Center — Guangzhou

Identifiers

NCT: NCT06350006 · SHR-A1904-301

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗